Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

Abstract

AIMS:

To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period.

METHODS AND RESULTS:

The study sample comprised 339 non-diabetic obese patients (body mass index > or = 30.0 kg/m2) aged 42-74. Patients received either bezafibrate retard 400 mg (178 patients) or placebo (161 patients) once daily. Development of new diabetes was recorded in 98 patients: in 56 (37.0%) from the placebo group vs. 42 (27.1%) from the bezafibrate group, (P log-rank=0.01). The median time (interquartile range) until onset of new diabetes was significantly delayed in patients on bezafibrate when compared with those on placebo: 4.0 (2.1-5.0) vs. 2.0 (0.5-3.5) years, P=0.002. Multivariable analysis identified bezafibrate treatment as an independent predictor of reduced risk of new diabetes with hazard ratio (HR) 0.59 [95% confidence interval (CI) 0.39-0.91]. Other significant variables associated with future overt type 2 diabetes in obese patients were triglycerides (50 mg/dL increment) with HR 1.15 (95% CI 1.02-1.28) and fasting glucose (10 mg/dL increment) with HR 2.27 (95% CI 1.83-2.81).

CONCLUSION:

Bezafibrate, when compared with placebo, reduced the incidence and delayed the onset of type 2 diabetes in obese patients over a long-term follow-up period.

• Authors: Alexander Tenenbaum, Michael Motro, Enrique Z Fisman, Yehuda Adler, Joseph Shemesh, David Tanne, Jonathan Leor, Valentina Boyko, Ehud Schwammenthal, Solomon Behar
• Journal: European heart journal (Eur Heart J) Vol. 26 Issue 19 Pg. 2032-8 (Oct 2005) ISSN: 0195-668X [Print] England
• PMID: 15872029 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Blood Glucose
• Hypolipidemic Agents
• Lipids
• Bezafibrate

Topics

• Adult
• Aged
• Bezafibrate (therapeutic use)
• Blood Glucose (metabolism)
• Body Mass Index
• Diabetes Mellitus, Type 2 (complications, metabolism, prevention & control)
• Female
• Humans
• Hypolipidemic Agents (therapeutic use)
• Lipids (blood)
• Male
• Middle Aged
• Obesity (complications, metabolism)
• Prospective Studies
• Treatment Outcome